INTENSITY THERAPEUTICS, INC. - 10-Q Filing
Intensity Therapeutics filed its 10-Q for the quarter ended March 31, 2026, reporting $10.2 million in cash and cash equivalents as of March 31, 2026, down from $11.9 million as of December 31, 2025. The company had $2.3 million in current liabilities and $9.9 million in stockholders' equity as of March 31, 2026. It also disclosed ongoing clinical trials, including the INVINCIBLE 3 Phase 3 Sarcoma and INVINCIBLE 4 Phase 2 Breast studies.
Tickers: $INTS